Department of Radiation Oncology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Front Immunol. 2021 Jul 21;12:680327. doi: 10.3389/fimmu.2021.680327. eCollection 2021.
We present a patient with locoregionally advanced laryngeal carcinoma, who experienced recurrence 2 months after surgery. We exploratively treated this patient with immunotherapy combined with targeted therapy with or without radiation therapy. The patient exhibited a significant and durable response. Thus far, there are no standard or effective second-line therapeutic modalities for recurrent locoregionally advanced laryngeal carcinoma. The efficacy of conventional chemotherapy with anti-epidermal growth factor receptor (anti-EGFR) remains unsatisfactory. The addition of immunotherapy resulted in substantial improvement in the progression-free survival (PFS) and overall survival (OS) of this patient. In this case, immunotherapy combined with anti-EFGR was administered, leading to good tumor response; based on this observation, radiotherapy was added to further intensify tumor control. This therapeutic strategy may be a novel option for recurrent locoregionally advanced squamous cell carcinoma of the head and neck.
我们报告一例局部晚期喉癌患者，该患者在手术后 2 个月复发。我们探索性地采用免疫治疗联合或不联合放疗的靶向治疗对该患者进行治疗，患者表现出显著和持久的缓解。迄今为止，对于复发性局部晚期喉癌尚无标准或有效的二线治疗方法。含抗表皮生长因子受体（anti-EGFR）的常规化疗疗效仍不理想。免疫治疗的加入显著改善了患者的无进展生存期（PFS）和总生存期（OS）。在本例中，我们联合应用了免疫治疗和抗 EGFR 治疗，肿瘤得到了很好的缓解；基于这一观察，我们加用了放疗以进一步强化肿瘤控制。这种治疗策略可能为复发性局部晚期头颈部鳞状细胞癌提供了一种新的选择。
